Vertex Pharmaceuticals Reports Strong Q4 Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy VRTX?
Source: NASDAQ.COM
Vertex Pharmaceuticals' stock rose 4.38% as it reached a 20-day high, reflecting positive investor sentiment following its recent earnings report.
The company reported a 10% year-over-year revenue growth for Q4, totaling $3.19 billion, primarily driven by the success of its cystic fibrosis drug ALYFTREK, which generated $380.1 million. Despite a decline in TRIKAFTA sales, Vertex's net income was robust at $1.2 billion, showcasing strong profitability. Additionally, the company provided optimistic revenue guidance for 2026, projecting between $12.95 billion and $13.1 billion, which aligns with market expectations and indicates confidence in future growth.
This strong financial performance and positive guidance have positioned Vertex favorably in the market, reflecting its ongoing commitment to innovation and growth in the cystic fibrosis sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 443.160
Low
414.00
Averages
515.88
High
604.00
Current: 443.160
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex Pharmaceuticals Submits BLA for IgAN Treatment
- Application Progress: Vertex Pharmaceuticals has completed its rolling Biologics License Application (BLA) submission for povetacicept, aimed at treating immunoglobulin A nephropathy (IgAN), with an expected FDA review completion within six months of acceptance, indicating the company's proactive stance in drug development.
- Priority Review Utilization: The application leverages a priority review voucher to expedite the FDA review process, thereby shortening the time to market and enhancing Vertex's position in the competitive biopharmaceutical landscape.
- Drug Mechanism: Povetacicept acts as a dual antagonist of B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) cytokines, both of which play crucial roles in the pathogenesis of various autoimmune diseases, highlighting its therapeutic potential for IgAN.
- Market Outlook: Given the rising demand for treatments for autoimmune diseases, the successful launch of povetacicept could present significant market opportunities for Vertex, potentially driving future revenue growth and enhancing shareholder value.
See More
CGGR Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: CGGR's 52-week low is $29.23 and high is $45.835, with the latest trade at $39.55, indicating price volatility within this range that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market sentiment.
See More
Trump Bull Market May End, Three Stocks Still Poised to Rise
- Market Uncertainty: The attack by the U.S. and Israel on Iran has disrupted traffic through the Strait of Hormuz, leading to rising oil prices that are expected to increase overall commodity prices and exacerbate inflationary pressures, thereby affecting investor confidence.
- Economic Slowdown: The U.S. GDP growth rate for Q4 2025 has slipped to 1.4%, coupled with a loss of 92,000 jobs in February, indicating that economic weakness may impact market performance, especially in the impending bear market.
- Investor Safe Haven: Berkshire Hathaway is viewed as a safe haven during market turbulence, with a massive cash stockpile that allows it to acquire quality stocks at lower prices during downturns, enhancing its risk resilience.
- Defensive Stock Advantage: Enbridge attracts many investors with a 5.2% dividend yield and a 31-year track record of dividend increases, while Vertex Pharmaceuticals' monopoly in treating cystic fibrosis positions it for potential growth even in a declining market.
See More
Prediction of the End of the Trump Bull Market
- Market Prediction Update: The conflict between the U.S. and Iran has led to rising oil prices, with the Producer Price Index (PPI) increasing by 3.4% year-over-year, significantly exceeding economists' expectations, prompting me to revise my stock market outlook and predict the end of the Trump bull market, which may lead to increased inflation.
- Economic Growth Slowdown: The U.S. GDP growth rate for Q4 2025 has slipped to 1.4%, partly due to the federal government shutdown, while the loss of 92,000 jobs highlights economic weakness, adding to market uncertainty.
- Fed Policy Dilemma: With the dual pressures of high inflation and a sluggish economy, the Federal Reserve faces a tough choice; cutting rates could exacerbate inflation, while raising them might further harm job growth, leaving the market uncertain about future policy directions.
- Defensive Stock Recommendations: Despite the potential end of the bull market, stocks like Berkshire Hathaway, Enbridge, and Vertex Pharmaceuticals are expected to rise; Berkshire's cash reserves and Enbridge's attractive dividends appeal to investors, while Vertex's unique position in healthcare makes it a strong candidate for growth.
See More
Long-Term Investment Potential in Strong Healthcare Stocks
- Strong Market Position: Johnson & Johnson (JNJ) maintains its leadership in the healthcare sector by continuously launching new products in pharmaceuticals and medical devices, effectively managing patent expirations and competitive pressures.
- Robust Financial Health: Johnson & Johnson boasts the highest credit rating, indicating its ability to meet financial obligations while retaining ample funds for investment, thereby strengthening its competitive edge for the next 20 years.
- Monopoly Market Advantage: Vertex Pharmaceuticals (VRTX) holds a monopoly in the cystic fibrosis drug market, benefiting from significant pricing power due to the absence of competitors, ensuring substantial revenue and profits for the next decade.
- Innovative Drug Development: Vertex is working on new medicines, including candidates for kidney disease and Type 1 diabetes, which are expected to drive strong returns beyond 2046, ensuring the company's long-term growth potential.
See More
Vertex Pharmaceuticals Shows Promising Future Prospects
- Core Business Stability: Vertex Pharmaceuticals continues to rely heavily on its cystic fibrosis drugs, Trikafta and Alyftrek, which drove a 9% year-over-year revenue increase to $12 billion in 2025, with expectations for core business growth at high single or low double-digit rates over the next year, solidifying its leadership in the global market.
- New Product Progress: The company anticipates generating at least $500 million in revenue from new products, Journavx and Casgevy, in 2025, indicating a strong performance in its non-cystic fibrosis portfolio and potentially marking the beginning of a new growth era for Vertex.
- Pipeline Advancements: Vertex plans to seek approval for povetacicept, a therapy for IgA nephropathy, by the end of March, with potential market entry by late 2026 or early 2027, which would further enhance its product lineup.
- Future Drug Approvals: The company also intends to request approval for Type 1 diabetes drug zimislecel this year and expects positive clinical trial results for inaxaplin, targeting APOL-1-mediated kidney disease, which could significantly boost its market competitiveness if successful in late 2026.
See More
Vertex Pharmaceuticals Submits BLA for IgAN Treatment
- Application Progress: Vertex Pharmaceuticals has completed its rolling Biologics License Application (BLA) submission for povetacicept, aimed at treating immunoglobulin A nephropathy (IgAN), with an expected FDA review completion within six months of acceptance, indicating the company's proactive stance in drug development.
- Priority Review Utilization: The application leverages a priority review voucher to expedite the FDA review process, thereby shortening the time to market and enhancing Vertex's position in the competitive biopharmaceutical landscape.
- Drug Mechanism: Povetacicept acts as a dual antagonist of B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) cytokines, both of which play crucial roles in the pathogenesis of various autoimmune diseases, highlighting its therapeutic potential for IgAN.
- Market Outlook: Given the rising demand for treatments for autoimmune diseases, the successful launch of povetacicept could present significant market opportunities for Vertex, potentially driving future revenue growth and enhancing shareholder value.
See More
CGGR Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: CGGR's 52-week low is $29.23 and high is $45.835, with the latest trade at $39.55, indicating price volatility within this range that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market sentiment.
See More
Trump Bull Market May End, Three Stocks Still Poised to Rise
- Market Uncertainty: The attack by the U.S. and Israel on Iran has disrupted traffic through the Strait of Hormuz, leading to rising oil prices that are expected to increase overall commodity prices and exacerbate inflationary pressures, thereby affecting investor confidence.
- Economic Slowdown: The U.S. GDP growth rate for Q4 2025 has slipped to 1.4%, coupled with a loss of 92,000 jobs in February, indicating that economic weakness may impact market performance, especially in the impending bear market.
- Investor Safe Haven: Berkshire Hathaway is viewed as a safe haven during market turbulence, with a massive cash stockpile that allows it to acquire quality stocks at lower prices during downturns, enhancing its risk resilience.
- Defensive Stock Advantage: Enbridge attracts many investors with a 5.2% dividend yield and a 31-year track record of dividend increases, while Vertex Pharmaceuticals' monopoly in treating cystic fibrosis positions it for potential growth even in a declining market.
See More
Prediction of the End of the Trump Bull Market
- Market Prediction Update: The conflict between the U.S. and Iran has led to rising oil prices, with the Producer Price Index (PPI) increasing by 3.4% year-over-year, significantly exceeding economists' expectations, prompting me to revise my stock market outlook and predict the end of the Trump bull market, which may lead to increased inflation.
- Economic Growth Slowdown: The U.S. GDP growth rate for Q4 2025 has slipped to 1.4%, partly due to the federal government shutdown, while the loss of 92,000 jobs highlights economic weakness, adding to market uncertainty.
- Fed Policy Dilemma: With the dual pressures of high inflation and a sluggish economy, the Federal Reserve faces a tough choice; cutting rates could exacerbate inflation, while raising them might further harm job growth, leaving the market uncertain about future policy directions.
- Defensive Stock Recommendations: Despite the potential end of the bull market, stocks like Berkshire Hathaway, Enbridge, and Vertex Pharmaceuticals are expected to rise; Berkshire's cash reserves and Enbridge's attractive dividends appeal to investors, while Vertex's unique position in healthcare makes it a strong candidate for growth.
See More
Long-Term Investment Potential in Strong Healthcare Stocks
- Strong Market Position: Johnson & Johnson (JNJ) maintains its leadership in the healthcare sector by continuously launching new products in pharmaceuticals and medical devices, effectively managing patent expirations and competitive pressures.
- Robust Financial Health: Johnson & Johnson boasts the highest credit rating, indicating its ability to meet financial obligations while retaining ample funds for investment, thereby strengthening its competitive edge for the next 20 years.
- Monopoly Market Advantage: Vertex Pharmaceuticals (VRTX) holds a monopoly in the cystic fibrosis drug market, benefiting from significant pricing power due to the absence of competitors, ensuring substantial revenue and profits for the next decade.
- Innovative Drug Development: Vertex is working on new medicines, including candidates for kidney disease and Type 1 diabetes, which are expected to drive strong returns beyond 2046, ensuring the company's long-term growth potential.
See More
Vertex Pharmaceuticals Shows Promising Future Prospects
- Core Business Stability: Vertex Pharmaceuticals continues to rely heavily on its cystic fibrosis drugs, Trikafta and Alyftrek, which drove a 9% year-over-year revenue increase to $12 billion in 2025, with expectations for core business growth at high single or low double-digit rates over the next year, solidifying its leadership in the global market.
- New Product Progress: The company anticipates generating at least $500 million in revenue from new products, Journavx and Casgevy, in 2025, indicating a strong performance in its non-cystic fibrosis portfolio and potentially marking the beginning of a new growth era for Vertex.
- Pipeline Advancements: Vertex plans to seek approval for povetacicept, a therapy for IgA nephropathy, by the end of March, with potential market entry by late 2026 or early 2027, which would further enhance its product lineup.
- Future Drug Approvals: The company also intends to request approval for Type 1 diabetes drug zimislecel this year and expects positive clinical trial results for inaxaplin, targeting APOL-1-mediated kidney disease, which could significantly boost its market competitiveness if successful in late 2026.
See More
